Organovo Holdings, Inc.

(Other OTC: ONVO)

July 16, 2013
Page 1 of 8 2013 Five Star Equities. All rights reserved.
Analyst
Rating
1
Contents
About Organovo Holdings, Inc.
Organovo Holdings, Inc. develops three-dimensional (3D) bioprinting technology for creating functional human
tissues on demand for research and medical applications. The companys 3D NovoGen bioprinting technology
works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers Novo-
Gen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting
research and development. The company was founded in 2007 and is based in San Diego, California.
Overview
Sector Healthcare
Industry Medical Laboratories &
Research
Employees 37
IPO Year N/A
Key Data
Last Trade $6.81
Price Range (52 week) 1.49 - 6.35
Avg Volume (13 Week) 739,581
Shares Outstanding 64,690,000
Mkt Cap $440,510,000
Enterprise Value $373,980,000
Book Value per Share $0.14
Dividend Yield --
1. Overview
2. Technical Data
3. Key Ratios
4. Earnings & Analyst
5.6. Financial Statements
7. Company Insiders
8. Disclaimer
Highlights & Recent Developments
Revenues of $0.2 million for the three months ended March 31, 2013 increased
approximately $0.1 million, or nearly 100%, over revenues of $0.1 million for the
same period in 2012. That increase can be atributed to $0.1 million of grant rev-
enue during the three months ended March 31, 2013.
Since inception, the Company has incurred
negative cash fows from operations. As of
March 31, 2013, the Company had cash and
cash equivalents of $15.6 million and an ac-
cumulated defcit of $66.4 million.
Organovo shares surged 13.31 percent to close at $6.81 a share Monday. The
stock traded between $6.44 and $7.22 on volume of 7.95 million shares traded.
On Monday, the company rang the opening bell on the New York Stock Exchange,
the company began trading on the NYSE on July 11th. Shares of Organovo have
gained approximately 162.0 percent year-to-date.
1
Analyst Consensus Rating based on publicly
reported third party data. See disclaimer.
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 2 of 8 2013 Five Star Equities. All rights reserved.
Technical Data
52 Week Low $1.49
52 Week High $6.35
50 Day Moving Average $4.19
200 Day Moving Average $4.04
Average Daily Volume (13Wk) 739,581
Price Information
Technical Signals Indicator Signal Strength Direction
Composite Indicator
Short-Term Indicators
Medium-Term Indicators
Long-Term Indicators
Trend Spotter Buy Maximum Strongest
7 Day Average Directional Indicator Buy Maximum Strongest
10 - 8 Day Moving Average Hilo Channel Buy Maximum Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Buy Minimum Strongest
20 Day Bollinger Bands Buy Maximum Strongest
40 Day Commodity Channel Index Buy Maximum Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Buy Minimum Strongest
50 Day Parabolic Time/Price Buy Maximum Strongest
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Buy Weak Strongest
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 3 of 8 2013 Five Star Equities. All rights reserved.
Valuation Ratios
Company Industry Sector
Company Industry Sector
Company Industry Sector
Company Industry Sector
Company Industry Sector
Company Industry Sector
Dividends
Growth Rates
Financial Strength
Proftability
Management Effectiveness
Company Industry Sector
Effciency
P/E Ratio (TTM) 0.00 36.15 33.33
P/E High - Last 5 Yrs. 0.00 48.22 34.70
P/E Low - Last 5 Yrs. 0.00 20.04 8.08
Beta 0.00 0.95 0.87
Price to Sales (TTM) 300.90 292.99 6.77
Price to Book (MRQ) 43.35 12.98 6.53
Price to Tangible Book (MRQ) 43.35 19.40 8.43
Price to Cash Flow (TTM) 0.00 21.38 23.33
Price to Free Cash Flow (TTM) 0.00 24.48 88.51
% Owned Institutions 0.0% 0.0% 0.0%
Dividend Yield 0.0% 0.6% 1.6%
Dividend Yield - 5 Year Avg. 0.0% 0.6% 3.4%
Dividend 5 Year Growth Rate 0.0% 6.5% 66.4%
Payout Ratio (TTM) 0.0% 13.9% 50.5%
Sales (MRQ) vs Qtr. 1 Yr. Ago 79.2% 110.9% 13.8%
Sales (TTM) vs TTM 1 Yr. Ago 18.5% 43.3% 16.4%
Sales - 5 Yr. Growth Rate 0.0% 10.1% 12.2%
EPS (MRQ) vs Qtr. 1 Yr. Ago 77.8% 45.0% 71.6%
EPS (TTM) vs TTM 1 Yr. Ago 58.1% 0.0% 0.0%
EPS - 5 Yr. Growth Rate 0.0% 9.7% 14.2%
Capital Spending - 5 Yr. Growth
Rate
0.0% 3.0% 20.3%
Quick Ratio (MRQ) 1.92 3.74 2.40
Current Ratio (MRQ) 1.93 5.07 3.31
LT Debt to Equity (MRQ) 0.17 34.63 6.78
Total Debt to Equity (MRQ) 0.28 51.46 11.00
Interest Coverage (TTM) 0.00 5.30 28.41
Gross Margin (TTM) 100.0% 47.2% 51.4%
Gross Margin - 5 Yr. Avg. 0.0% 52.0% 52.5%
EBITD Margin (TTM) -909.9% 0.0% 0.0%
EBITD - 5 Yr. Avg. 0.0% -22.6% 0.0%
Operating Margin (TTM) -929.9% -1586.1% 1.3%
Operating Margin - 5 Yr. Avg. 0.0% -37.4% 15.3%
Pre-Tax Margin (TTM) -1748.6% -2826.9% -8.5%
Pre-Tax Margin - 5 Yr. Avg. 0.0% -39.3% 15.6%
Net Proft Margin (TTM) -1748.6% -1442.9% -0.4%
Net Proft Margin - 5 Yr. Avg. 0.0% -41.5% 11.4%
Effective Tax Rate (TTM) 0.0% 14.6% 26.5%
Effective Tax Rate - 5 Yr. Avg. 0.0% 24.5% 30.8%
Return On Assets (TTM) -157.9% 0.4% 14.6%
Return On Assets - 5 Yr. Avg. 0.0% -1.3% 14.3%
Return On Investment (TTM) -236.3% -2.4% 18.8%
Return On Investment - 5 Yr Avg 0.0% -5.5% 19.1%
Return On Equity (TTM) 0.0% -2.9% 19.8%
Return On Equity - 5 Yr. Avg. 0.0% -11.4% 19.4%
Revenue/Employee (TTM) 41,678 7,741,411
Net Income/Employee (TTM) -728,788 -387,667
Receivable Turnover (TTM) 0.00 16.57 7.07
Inventory Turnover (TTM) 0.00 3.23 3.84
Asset Turnover (TTM) 0.09 0.49 1.19
Key Statistics & Ratios
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 4 of 8 2013 Five Star Equities. All rights reserved.
Earnings & Analyst Data
Analyst Recommendation Summary
CURRENT 1 MONTH
AGO
2 MONTHS
AGO
3 MONTHS
AGO
Strong Buy (1.0) NA NA NA NA
Moderate Buy (2.0) NA NA NA NA
Hold (3.0) NA NA NA NA
Moderate Sell (4.0) NA NA NA NA
Strong Sell (5.0) NA NA NA NA
Mean Recommendation NA NA NA NA
Current Consensus NA
EPS Historical Surprises
Estimates Actual Difference Surprise %
Dividend Payments
Dividend
Amount
Ex-dividend Date Payable
Date
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
EPS Estimates
# of Ests. Mean Est. High Est. Low Est.
Mean Target:
High Target: N/A
Low Target: N/A
No. of Brokers: N/A
Analyst Upgrades & Downgrades
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 5 of 8 2013 Five Star Equities. All rights reserved.
Financial Statements
Figures in Millions of US Dollars (exept per share values)
Balance Sheet Annual Quarterly
Period Ending 30-Dec-12 30-Dec-11 29-Jun-11 30-Dec-12 29-Sep-12 29-Jun-12 30-Mar-12
Assets
Cash And Cash Equivalents 15 0 0 15 8 9 10
Short Term Investments -- -- -- -- -- -- --
Net Receivables 0 -- -- 0 0 -- --
Inventory 0 0 -- 0 0 1 0
Other Current Assets -- -- -- -- -- -- --
Total Current Assets -- -- -- -- -- -- --
Long Term Investments -- -- -- -- -- -- --
Property Plant and Equipment 1 0 -- 1 1 0 0
Goodwill -- -- -- -- -- -- --
Intangible Assets -- -- -- -- -- -- --
Accumulated Amortization -- -- -- -- -- -- --
Other Assets 1 0 0 1 0 0 0
Deferred Long Term Asset Charges -- 0 -- -- -- -- --
Total Assets 17 1 0 17 9 10 11
Liabilities
Accounts Payable 1 1 0 1 36 81 48
Short/Current Long Term Debt -- -- -- -- -- -- --
Other Current Liabilities -- -- -- -- -- -- --
Total Current Liabilities -- -- -- -- -- -- --
Long Term Debt 0 1 -- 0 0 -- --
Other Liabilities 21 1 -- 21 -- -- --
Deferred Long Term Liability Charges -- 0 -- -- 0 0 0
Total Liabilities 22 3 0 22 36 81 49
Stockholders Equity
Misc Stocks Options Warrants -- -- -- -- -- -- --
Redeemable Preferred Stock -- -- -- -- -- -- --
Preferred Stock -- -- -- -- -- -- --
Common Stock 0 0 0 0 0 0 0
Retained Earnings (50) (7) (0) (50) (41) (79) (44)
Treasury Stock -- -- -- -- -- -- --
Capital Surplus 45 5 0 45 13 7 6
Other Stockholder Equity -- -- -- -- -- -- --
Total Stockholder Equity (5) (2) (0) (5) (27) (72) (37)
Net Tangible Assets (Book Value) (5) (2) (0) (5) (27) (72) (37)
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 6 of 8 2013 Five Star Equities. All rights reserved.
Income Statement Annual Quarterly
Period Ending 30-Dec-12 30-Dec-11 29-Jun-11 30-Dec-12 29-Sep-12 29-Jun-12 30-Mar-12
Total Revenue 1 1 -- 0 0 0 0
Cost of Revenue -- 0 -- -- -- -- --
Gross Income 1 1 -- 0 0 0 0
Research and Development 3 1 -- 1 1 1 1
Selling General and Administrative 7 2 0 2 3 1 1
Non Recurring -- -- 0 -- -- -- --
Others -- -- -- -- -- -- --
Total Operating Expenses 11 3 0 3 4 2 1
Operating Income or Loss (9) (2) (0) (3) (4) (1) (1)
Total Other Income(Expenses) Net (33) (0) -- (7) 42 (34) (33)
Earnings Before Interest And Taxes (42) (2) (0) (10) 38 (35) (34)
Interest Expense 1 2 -- -- -- -- 3
Income Tax Expense -- -- -- -- -- -- --
Net Income From Continuing Ops (44) (4) (0) (10) 38 (35) (37)
Other Items not from Continuing Operations -- -- -- -- -- -- --
Net Income attributable to the Company (44) (4) (0) (10) 38 (35) (37)
Preferred Stock And Other Adjustments -- -- -- -- -- -- --
Net Income Applicable To Common Shares (44) (4) (0) (10) 38 (35) (37)
Cash Flow Statement Annual Quarterly
Period Ending 30-Dec-12 30-Dec-11 29-Jun-11 30-Dec-12 29-Sep-12 29-Jun-12 30-Mar-12
Net Income (44) (4) (0) (10) 38 (35) (37)
Operating Activities
Depreciation 2 1 0 1 0 0 1
Adjustments To Net Income 32 1 0 7 (41) 34 33
Changes In Accounts Receivables (0) 0 -- (0) (0) -- --
Changes In Liabilities 0 1 0 0 0 (0) (0)
Changes In Inventories (0) (0) -- (0) (0) (0) (0)
Changes In Other Operating Activities (0) (0) -- (0) 0 (0) (0)
Total Cash Flow From Operating Activities (10) (2) (0) (2) (2) (2) (4)
Investing Activities
Capital Expenditures (0) (0) -- (0) (0) (0) (0)
Investments (0) -- -- -- -- (0) (0)
Other Cash fows from Investing Activities -- (0) (0) -- -- -- --
Total Cash Flows From Investing Activities (0) (0) (0) (0) (0) (0) (0)
Financing Activities
Dividends Paid -- -- -- -- -- -- --
Sale Purchase of Stock 25 -- -- 9 2 0 14
Net Borrowings (0) 2 -- (0) (0) -- (0)
Other Cash Flows from Financing Activities -- -- -- -- -- -- --
Total Cash Flows From Financing Activities 25 2 -- 9 2 0 14
Effect Of Exchange Rate Changes -- -- -- -- -- -- --
Other Liabilities 21 1 -- 21 -- -- --
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 7 of 8 2013 Five Star Equities. All rights reserved.
Company Insiders
Company Offcers
Name Age Since Current Position Basic Compensation Options Options Value
Keith Murphy 41 2012 Chairman of the Board, President, Chief Executive Of-
fcer
$677,347 -- --
Barry Michaels 63 2011 Chief Financial Offcer, Corporate Secretary $1,785,170 -- --
Sharon Presnell 44 2011 Executive Vice President - Research and Development,
Chief Technology Offcer
$616,832 -- --
Michael Renard 54 2012 Executive Vice President - Commercial Operations $958,328 -- --
Eric David 41 2012 Chief Strategy Offcer $973,114 -- --
Andras Forgacs 36 2012 Director -- -- --
Robert Baltera 47 2012 Independent Director -- -- --
James Glover 61 2012 Independent Director -- -- --
Tamar Howson 64 2013 Independent Director -- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
Insider Transactions
Trading Date Name Title Type Shares Traded Price
12 Feb 2013 MURPHY KEITH Chief Executive Offcer Sell 24690 $4.59
20 Dec 2012 MICHAELS BARRY D Chief Financial Offcer Buy 10000 $0.80
20 Dec 2012 BALTERA ROBERT JR Director Buy 25000 $0.80
22 Aug 2012 MICHAELS BARRY D Chief Financial Offcer Sell 79687 $2.10
5 Aug 2012 MICHAELS BARRY D Chief Financial Offcer Buy 750000 $0.00
5 Aug 2012 MURPHY KEITH Chief Executive Offcer Buy 200000 $0.00
1 Aug 2012 PRESNELL SHARON COLLINS Chief Technology Offcer Buy 224064 $0.08
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
Organovo Holdings, Inc.
(Other OTC: ONVO)
July 16, 2013
Page 8 of 8 2013 Five Star Equities. All rights reserved.
Disclaimer
This report is provided for general information purposes only. The information contained in this report is not to
be construed as advice and should not be confused as any sort of advice. Information has been obtained from
sources considered to be reliable, but we do not guarantee the information is accurate, correct, complete, or
timely or make any warranties regarding results from its usage. Past performance is not a guarantee of future re-
sults. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Redis-
tribution or reproduction is prohibited without written permission.
Five Star Equities (hereafter Five Star) is owned and operated by Providence Media Strategies LLC (hereafter Provi-
dence). Five Star / Providence is an online fnancial newsletter focused on coverage of small-cap and large-cap public
companies. Five Star / Providence is not a registered broker dealer or a registered investment advisor. No information ac-
cessed through the Five Star / Providence Web site or this report constitutes a recommendation or solicitation to buy, sell
or hold any security in any jurisdiction.
All bullish, bearish, neutral or other analyst ratings are based on publically available third party analyst ratings. Specifcal-
ly, both the Analyst Consensus Rating and Current Analyst Consensus Data are directly based on information published
by money.msn.com.
Five Star / Providence receives compensation from third party organizations for advertising services provided in the form
of email newsletters. Five Star / Providence and its affliates, offcers, directors and agents have been compensated for
featured company coverage and therefore information should not be construed as unbiased.
Five Star / Providence and its outside sources use certain data derived from the U.S. Securities and Exchange Commis-
sion (SEC) flings, public information and data compiled by other vendors. The reader should verify all claims and do his/
her own research and due diligence before investing in any securities mentioned. Guests of Providences website, www.
fvestarequities.com, readers of Five Star / Providences distributed reports/releases/advertisements, and other interested
parties assume full responsibility for the accuracy of all SEC fling data, compiled data from other sources including data
from the issuing Company, and are urged to confrm that data with the specifc issuing Company. Five Star / Providence
will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of information in
this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use
of information, products or services from any person or entity including but not limited to lost profts, loss of opportunities,
trading losses, and damages that may result from any incompleteness or inaccuracy in the profled company information
Five Star / Providence and its data vendors do not assume any responsibility or liability for any investor decision made as
a result of accessing fundamental and/or fnancial data on any profled company as a consequence of viewing our ma-
terials. Five Star / Providence encourages its readers and visitors to its website to invest carefully and read the investor
information available on the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/or the
National Association of Securities Dealers (NASD) at www.nasd.com. Investors interested in purchasing securities are
advised to read the Prospectus, 10K, 10Q, other relevant public documents in full, request Company fnancial information
and to conduct their own research and due diligence.
Statements made in this release may include projections, made in reliance on the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Five Star / Providence has made every reasonable effort to ensure that the
information and assumptions on which these statements and projections are based are current, reasonable, and com-
plete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results
or other expectations expressed in this release. Five Star / Providence makes these statements and projections in good
faith, neither Five Star / Providence nor its management can guarantee that the transactions will be consummated or that
anticipated future results will be achieved.